XML 17 R44.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

The Company (Details) - USD ($) $ in Thousands |  |  |  | 1 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 25, 2019 | Aug. 23, 2018 | Apr. 20, 2017 | Aug. 31, 2014 | Dec. 31, 2019 | Sep. 30, 2019 | Dec. 31, 2018 | Aug. 31, 2015
Minimum age of ambulatory patient |  |  |  | 5 years |  |  |  |
Accumulated deficit |  |  |  |  | $ (1,190,499) |  | $ (938,923) |
Convertible Senior Notes, 1.5%, Due September 15, 2026 | Convertible debt |  |  |  |  |  |  |  |
Interest rate |  |  |  |  | 1.50% | 1.50% |  |
3.00% Convertible senior notes due 2022 | Convertible debt |  |  |  |  |  |  |  |
Interest rate |  |  |  |  |  |  |  | 3.00%
Marathon Pharmaceuticals, LLC | Non-collaborative Arrangement Transactions |  |  |  |  |  |  |  |
Cash consideration |  |  | $ 75,000 |  |  |  |  |
Equity interest issued or issuable, number of shares (in shares) |  |  | 6,683,598 |  |  |  |  |
Numerator for calculation of number of shares of equity interests issued to acquire entity |  |  | $ 65,000 |  |  |  |  |
Trading day period |  |  | 15 days |  |  |  |  |
Development milestone payment obligations |  |  | $ 50,000 |  |  |  |  |
Agilis |  |  |  |  |  |  |  |
Cash consideration |  | $ 49,221 |  |  |  |  |  |
Equity interest issued or issuable, number of shares (in shares) |  | 3,500,907 |  |  |  |  |  |
Numerator for calculation of number of shares of equity interests issued to acquire entity |  | $ 150,000 |  |  |  |  |  |
Trading day period |  | 10 days |  |  |  |  |  |
Development milestone payment obligations |  | $ 40,000 |  |  | $ 40,000 |  |  |
Agilis | Non-collaborative Arrangement Transactions |  |  |  |  |  |  |  |
Development milestone payment obligations |  | $ 40,000 |  |  | 40,000 |  |  |
Maximum | Agilis |  |  |  |  |  |  |  |
Development milestone payment obligations |  |  |  |  | 60,000 |  |  |
Net sales milestones |  |  |  |  | 150,000 |  |  |
Maximum | BioElectron |  |  |  |  |  |  |  |
Development milestone payment obligations |  |  |  |  | 200,000 |  |  |
BioElectron |  |  |  |  |  |  |  |
Cash consideration | $ 10,000 |  |  |  |  |  |  |
Development milestone payment obligations |  |  |  |  | $ 200,000 |  |  |
Loan advance | 4,000 |  |  |  |  |  |  |
Escrow deposit disbursements related to property acquisition | 1,500 |  |  |  |  |  |  |
BioElectron | Maximum |  |  |  |  |  |  |  |
Net sales milestones | $ 200,000 |  |  |  |  |  |  |

X
- Definition Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period + References No definition available. + Details
Name: | ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod
Namespace Prefix: | ptct_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity + References No definition available. + Details
Name: | ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligations
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loan Advance + References No definition available. + Details
Name: | ptct_LoanAdvance
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the minimum age of ambulatory patient. + References No definition available. + Details
Name: | ptct_MinimumAgeOfAmbulatoryPatient
Namespace Prefix: | ptct_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586 + Details
Name: | us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ptct_BioElectronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |